Center-Authored Papers

Filters: Author is Yu, Xuesong  [Clear All Filters]
2017
Hou J, Wang S, Jia M, Li D, Liu Y, Li Z, Zhu H, Xu H, Sun M, Lu L et al..  2017.  A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine.. Journal of immunology (Baltimore, Md. : 1950). Abstract
Zurawski G, Shen X, Zurawski S, Tomaras GD, Montefiori DC, Roederer M, Ferrari G, Lacabaratz C, Klucar P, Wang Z et al..  2017.  Superiority in Rhesus Macaques of Targeting HIV-1 Env Gp140 to CD40 Versus LOX-1 in Combination with Replication Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.. Journal of virology. Abstract
Wang Y, Whittall T, Neil S, Britton G, Mistry M, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Yu X et al..  2017.  A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection.. Scientific reports. 7(1):1057. Abstract
Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody AM, Frahm N, Montefiori DC, Hay CM, Goepfert PA et al..  2017.  Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.. PloS one. 12(7):e0179597. Abstract
2016
Cosgrove CA, Lacey CJ, Cope AV, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki E et al..  2016.  Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.. PloS one. 11(5):e0152038. Abstract
Fong Y, Yu X.  2016.  Transformation Model Choice in Nonlinear Regression Analysis of Fluorescence-based Serial Dilution Assays.. Statistics in biopharmaceutical research. 8(1):1-11. Abstract
2015
Jin X, Morgan C, Yu X, De Rosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC.  2015.  Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.. Vaccine. 33(20):2347-53. Abstract
Pettifor A, Corneli A, Kamanga G, McKenna K, Rosenberg NE, Yu X, Ou S-S, Massa C, Wiyo P, Lynn D et al..  2015.  HPTN 062: A Pilot Randomized Controlled Trial Exploring the Effect of a Motivational-Interviewing Intervention on Sexual Behavior among Individuals with Acute HIV Infection in Lilongwe, Malawi.. PloS one. 10(5):e0124452. Abstract
Cumberland WN, Fong Y, Yu X, Defawe O, Frahm N, De Rosa S.  2015.  Nonlinear Calibration Model Choice between the Four and Five-Parameter Logistic Models.. Journal of biopharmaceutical statistics. 25(5):972-83. Abstract
2014
Corneli A, Pettifor A, Kamanga G, Golin C, McKenna K, Ou S-S, Hamela G, Massa C, Martinson F, Tharaldson J et al..  2014.  HPTN 062: A Feasibility and Acceptability Pilot Intervention to Reduce HIV Transmission Risk Behaviors Among Individuals with Acute and Early HIV Infection in Lilongwe, Malawi.. AIDS and behavior. Abstract
2013
Gilbert PB, Yu X, Rotnitzky A.  2013.  Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials.. Statistics in medicine. Abstract
Fong Y, Sebestyen K, Yu X, Gilbert P, Self S.  2013.  nCal: an R package for non-linear calibration.. Bioinformatics (Oxford, England). Abstract
Kunwar P, Hawkins N, Dinges WL, Liu Y, Gabriel EE, Swan DA, Stevens CE, Maenza J, Collier AC, Mullins JI et al..  2013.  Superior Control of HIV-1 Replication by CD8+ T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design.. PloS one. 8(5):e64405. Abstract
2012
Todd CA, Greene KM, Yu X, Ozaki DA, Gao H, Huang Y, Wang M, Li G, Brown R, Wood B et al..  2012.  Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.. Journal of immunological methods. 375(1-2):57-67. Abstract
2010
Yu X, Randolph TW, Tang H, Hsu L.  2010.  Detecting genomic aberrations using products in a multiscale analysis.. Biometrics. 66(3):684-93. Abstract
Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self SG, Williams C, Gorny MK, Zolla-Pazner S.  2010.  Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.. PloS one. 5(4):e10254. Abstract
2009
Sather ND, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self SG, Kalams S et al..  2009.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.. Journal of virology. 83(2):757-69. Abstract